Serum leptin in Peritoneal Dialysis: Is It a Useful Biomarker Following Peritonitis?

over the past 30 years, peritoneal dialysis (PD) has become an established form of renal replacement therapy that is currently used to treat over 200,000 patients with end-stage renal disease worldwide (1). Patient survival on PD is at least comparable, and possibly superior, to that of patients receiving hemodialysis (hD) (2). however, the rate of technique failure, including both surgical technical and membrane failure, associated with PD is higher than that associated with hD (3). The identification of a biomarker that can reliably identify PD patients at high risk of technique failure at an early stage would be highly valuable.